PepGen Inc. Reports $17.8 Million Net Loss in Q2 2026, Focuses on PGN-EDODM1 Development

PepGen Inc. reported its financial results for the second quarter of 2026, revealing a net loss of $17.8 million, a decrease from a net loss of $23.1 million in the same period last year. The company's total operating expenses for the quarter were $18.9 million, down from $23.9 million in the prior year, primarily due to a significant reduction in research and development costs, which fell from $18.4 million to $12.5 million. This decline is attributed to the discontinuation of the company's DMD program and a decrease in clinical trial expenses. General and administrative expenses increased slightly to $6.4 million from $5.5 million, driven by higher personnel-related costs.

For the first half of 2026, PepGen's net loss was $35.6 million, compared to $53.3 million for the same period in 2025. The company reported total operating expenses of $37.9 million, down from $55.3 million, with research and development expenses decreasing from $43.8 million to $25.5 million. The reduction in expenses reflects the company's strategic decision to focus on its lead product candidate, PGN-EDODM1, while winding down other programs. The company also reported an increase in interest income, which rose to $2.3 million for the first half of 2026, compared to $2.0 million in the previous year.

PepGen's cash, cash equivalents, and marketable securities totaled $117.2 million as of June 30, 2026, providing sufficient liquidity to fund operations into the fourth quarter of 2027. The company has not generated any revenue from product sales and has relied on equity financing to support its operations. Notably, PepGen completed several financing activities, including a public offering in September 2025 that raised $107.6 million in net proceeds. The company continues to explore additional funding options to support its ongoing clinical trials and research activities.

Operationally, PepGen is advancing its clinical development program for PGN-EDODM1, which is designed for the treatment of myotonic dystrophy type 1 (DM1). The company has conducted multiple studies, including the FREEDOM and FREEDOM2 trials, with positive safety and efficacy data reported. The FREEDOM2 study is currently on partial clinical hold in the U.S., and PepGen is working with the FDA to address outstanding questions. The company anticipates reporting data from the 10 mg/kg cohort of the FREEDOM2 study in November 2026, with further results expected in 2027.

Looking ahead, PepGen remains focused on its strategic objectives, including the continued development of PGN-EDODM1 and potential future product candidates. The company acknowledges the inherent risks and uncertainties in drug development, including the need for additional funding and the potential for delays in clinical trials. PepGen's management believes that its current financial resources will support its planned operations, but the company may need to raise additional capital to sustain its development efforts in the future.